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A B S T R A C T
The study of proteins is central to unraveling (patho)physiological processes and has contributed greatly to our
understanding of biological systems. Corresponding studies often employ procedures to enrich proteins from
their biological matrix using antibodies or other aﬃnity binders coupled to beads with a large surface area and a
correspondingly high binding capacity. Striving for maximal binding capacity may, however, not always be
required or desirable, for example for proteins of low abundance. Here we describe a simpliﬁed im-
munoprecipitation in 96-well ELISA format (IPE) approach for fast and easy enrichment of proteins. The ap-
plicability of this approach for enriching low-abundant proteins was demonstrated by an IPE-based quantitative
workﬂow using liquid chromatography-mass spectrometry (LC-MS) for the soluble Receptor of Advanced
Glycation End-products (sRAGE), a promising biomarker in chronic obstructive pulmonary disease (COPD). The
method was validated according to U.S. Food and Drug Administration (FDA) and European Medicines Agency
(EMA) guidelines and enabled accurate quantitation of sRAGE between 0.1 and 10 ng/mL in 50 µL serum. The
assay showed substantial correlation with the two most commonly-used sRAGE immunoassays (ELISAs) (R2-
values between 0.7 and 0.8). However, the LC-MS method reported 2–4 times higher sRAGE levels compared to
the ELISAs, which is largely due to a suboptimal amount of capturing antibody and/or calibration strategy used
by the immunoassays. In conclusion, our simpliﬁed IPE approach proved to be an eﬃcient strategy for enriching
the low-abundant protein sRAGE from serum and may provide an easy to use platform for enriching other (low-
abundant) proteins from complex, biological matrices.
1. Introduction
Studying proteins in complex, biological matrices is a common
feature of (bio)medical research and has contributed considerably to
our current understanding of life processes. For studies on protein ex-
pression, structure, and interactions, a variety of analytical techniques
is being deployed including gel electrophoresis, liquid chromatography
and mass spectrometry, which may all require speciﬁc protein enrich-
ment procedures depending on the aim of a study and/or the protein(s)
of interest [1,2]. Immunopuriﬁcation is an eminent example of such
enrichment techniques and uses speciﬁc ‘bait’ proteins to selectively
bind and purify the targets of interest (e.g. antigens) [3]. Antibodies are
generally used to capture proteins or even protein complexes, though
conversely, antigens may also serve as baits to capture antibodies which
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may be valuable for analyzing autoantibodies [4,5]. The former ap-
proach is a widely-used application of antibodies in basic and applied
scientiﬁc research, and has contributed to the conception of antibodies
being the ‘workhorses’ of (bio)medical experiments [6].
Besides bait proteins, immunopuriﬁcation strategies require a
(solid) support to which a bait protein is or can be coupled thereby
allowing to separate the bait/target-complex from the original matrix
[7]. Examples of such supports comprise gel-based (e.g. agarose) and
magnetic beads each having speciﬁc advantages and disadvantages in
terms of binding capacity, protocol ﬂexibility and throughput as well as
the degree and extent of non-speciﬁc binding [8]. As alternative to
bead-based supports, (adsorptive) microtiter plates commonly used for
immunoassays, have also been employed for immunoaﬃnity enrich-
ment purposes [9–12]. Some hybrid assays based on immunoaﬃnity
enrichment and digestion in microtiter plates followed by LC-MS de-
tection demonstrated eﬃcient enrichment of low abundant proteins
[9,10]. A similar approach (referred to as immunoprecipitation in 96-
well ELISA format, or IPE) showed matching capabilities, though IPE
features a decoupled enrichment and digestion strategy and thereby
also allows to study intact proteins, for example by top-down pro-
teomics or Western Blot analysis [11]. This approach utilizes microtiter
plates coated with Protein (A/)G to which antibodies are bound and
covalently coupled with disuccinimidyl suberate (DSS). Although this
methodology has many potential applications, examples of such ap-
plications are absent in literature, which may be because IPE's ad-
vantages compared to (magnetic) beads-based alternatives are less
pronounced due to its dependence on Protein (A/)G-coated plates.
The soluble Receptor of Advanced Glycation End-products (sRAGE)
is a potential biomarker for chronic obstructive pulmonary disease
(COPD) and an example of a clinically relevant protein of low abun-
dance [13]. sRAGE is formed after proteolytic cleavage of membrane-
bound RAGE, a pattern recognition receptor involved in pro-in-
ﬂammatory signaling pathways [14]. In addition, sRAGE can be formed
upon alternative splicing of the AGER gene thereby leading to a RAGE
splice variant known as endogenous secretory RAGE (esRAGE) [15].
Circulating RAGE has anti-inﬂammatory properties by acting as a decoy
receptor for pro-inﬂammatory RAGE ligands and also by inhibiting
homo-dimerization of membrane-bound RAGE which is presumed to be
essential for RAGE activation [16–18]. In several (large-scale) bio-
marker studies, sRAGE was put forward as useful biomarker in COPD,
particularly with respect to the presence and progression of emphy-
sema, and sRAGE was consequently considered for biomarker qualiﬁ-
cation by the U.S. Food and Drug Administration (FDA) [19,20].
However, current knowledge about sRAGE is strongly depending on
measurements with “research-grade” enzyme-linked immunosorbent
assays (ELISA) from a single vendor, and appropriately validated assays
are lacking [19]. Furthermore, it is known that sRAGE is regulated by
alternative splicing and post translational modiﬁcations, including
proteolytic cleavage and N-linked glycosylation [21]. Circulating RAGE
thus likely comprises a series of related proteins (also referred to as
‘protein species’ or ‘proteoforms’) with potentially diﬀerent functions,
activities or ligand speciﬁcities [21–23]. It is therefore not only essen-
tial that sRAGE assays for clinical use are adequately validated, but
these assays also need to be adequately characterized with respect to
the exact forms of circulating RAGE that are being quantiﬁed.
In this study, we present an eﬃcient, fast, and easy to use enrich-
ment strategy for proteins in complex matrices on the basis of anti-
bodies directly immobilized on high aﬃnity microtiter plates. This
methodology was combined with liquid chromatography-mass spec-
trometry (LC-MS) for quantifying sRAGE in human serum based on
speciﬁc peptides in its N-terminal region which is essential for the
binding of most RAGE ligands [14,24]. The method was validated ac-
cording to FDA and European Medicines Agency (EMA) guidelines with
a lower limit of quantiﬁcation (LLOQ) of 0.1 ng/mL [25,26]. The va-
lidated LC-MS assay for sRAGE is expected to contribute to the devel-
opment of sRAGE as biomarker in COPD.
2. Experimental
2.1. Chemicals and materials
Recombinant human RAGE encompassing the extracellular domain
of this protein (Cat. No. C423; UniProtKB ID ‘Q15109′; Ala23-Ala344
with C-terminal hexa-histidine tag) was purchased from Novoprotein
(Summit, NJ, U.S.A.), monoclonal anti-RAGE antibody (Cat. No.
MAB11451; clone 176902) was obtained from R&D Systems (Abingdon,
U.K.), and stable-isotope-labeled RAGE peptides (i.e. IGEPLVLK*&
VLSPQGGGPWDSVAR*) were synthesized by Pepscan Presto (Lelystad,
The Netherlands). Acetonitrile (ACN; LC-MS grade) was obtained from
Biosolve (Valkenswaard, The Netherlands) and sequencing grade
modiﬁed trypsin was purchased from Promega (Madison, WI, U.S.A.).
Nunc-Immuno™ MicroWell™ 96 wells plates with MaxiSorp™ coating
(Cat. No. M9410), bovine serum albumin (BSA; Cat. No. A7638), and
phosphate buﬀered saline (PBS; 10× ; Cat. No. D1408) as well as all
other chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands).
2.2. Serum samples
Serum was obtained from healthy volunteers and was pooled for
preparation of the quality control (QC-)samples. Pooled serum was used
directly as QC-medium sample, diluted eight times with 1% BSA in
1×PBS, pH 7.4 (Surrogate Matrix) for preparation of the QC-low
sample, or fortiﬁed with 5 ng/mL recombinant RAGE to obtain the QC-
high sample. Recovery and spike recovery experiments were carried out
using six diﬀerent sources of human serum from (seemingly) healthy
subjects (all from Seralab). Spike recovery experiments were further-
more performed on a lipemic serum sample (triglyceride content>
150mg/dL; obtained from Seralab) and a hemolytic sample which was
prepared by adding freeze-thawed whole blood (2%) to human serum.
2.3. Calibrants and internal standard
Lyophilized RAGE was dissolved in Milli-Q water to obtain a
200 µg/mL solution (based on the quantity as declared by the supplier)
which was diluted to 100 µg/mL with 1×PBS, pH 7.4 (PBS Buﬀer)
after checking protein purity by SDS-PAGE and MALDI-TOF MS, which
did not reveal the presence of proteins other than sRAGE. The resulting
stock solution was sequentially diluted to 100 ng/mL with Surrogate
Matrix (see Serum samples section above), and calibration samples
were prepared at 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 8.0 and 10.0 ng/mL. For the
internal standard (IS), SIL-peptides (supplied as 5 pmol/µL solutions in
5% ACN) were mixed 1:1 and diluted to 5 fmol/µL with 1% dimethyl
sulfoxide (DMSO) in water.
2.4. Simpliﬁed IPE protocol
(1: plate coating) The plate was coated using 100 µL aliquots of
PBS Buﬀer containing 0.5 µg of antibody (from a 200 µg/mL stock so-
lution; antibody was reconstituted in PBS Buﬀer) which were added to
microplate wells, followed by overnight incubation at room tempera-
ture. (2: plate blocking) After removal of unbound antibody by three
washing steps with 300 µL Wash Buﬀer (0.05% Tween-20 in PBS
Buﬀer), uncoated surface was blocked with 300 µL Surrogate Matrix for
60min while shaking on a plate shaker (600 RPM; room temperature).
(3: immunocapture) Wells were washed three times with 300 µL Wash
Buﬀer, and 100 µL of Sample Solution (for which 60 µL of serum was
pre-mixed with 60 µL Surrogate Matrix to allow quantitative transfer of
Sample Solution) was added to the wells for the immunocapture of
sRAGE (120min; 600 RPM; room temperature). (4: analyte collection)
The wells were washed three times with 300 µL Wash Buﬀer, and
sRAGE was eluted from the antibodies with 100 µL 0.1% aqueous tri-
ﬂuoroacetic acid (TFA) solution (10min; 600 RPM; room temperature).
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The IPE eluate was collected in low binding tubes (Eppendorf; Cat. No.
022431081) using low binding tips (VWR; Cat. No. 613-0891), and the
samples were dried in a vacuum centrifuge at 60 °C.
2.5. In-solution digestion
Proteins were reconstituted in 50 µL Digestion Buﬀer (100 fmol/mL
SIL-peptides in 50mM ammonium bicarbonate (ABC)). Subsequently,
disulﬁde bonds were reduced with 10mM dithiothreitol (DTT) (5 µL
110mM DTT in 50mM ABC) for 30min (60 °C; 600 RPM), and thiols
were alkylated with 20mM iodoacetamide (IAM) (5 µL 240mM IAM in
50mM ABC) for 30min in the dark (room temperature). After
quenching the excess of IAM with a 0.5M excess of DTT (6 µL 110mM
DTT in 50mM ABC), 100 ng trypsin was added to each sample, and
proteins were digested by overnight incubation (37 °C; 600 RPM). The
IPE digests were acidiﬁed by adding 2 µL of 50% formic acid (FA), and
15 µL of sample was analyzed by LC-MS.
2.6. LC-MS
Analyses were performed with a Waters Ionkey/MS system using an
ACQUITY M-Class UPLC and a XEVO TQ-S mass spectrometer (Milford,
MA, U.S.A.). Chromatographic separation was achieved on a C18-
bonded Waters iKey HSS T3 Separation Device (1.8 µm particles, 100 Å
pore size, 150 µm ×100mm; Cat. No. 186007261) which was kept at
40 °C, using 0.1% FA in H2O as mobile phase A and 0.1% FA in ACN as
mobile phase B. Samples were loaded onto a Dionex Acclaim
PepMap100 C18 trap column (5 µm particles, 100 Å pore size, 300 µm
×5mm; Cat. No. 160454) for 2.5min with 3% B at 20 µL/min.
Subsequently, peptides were separated on the analytical column at
3 µL/min with a 10min linear gradient from 3% to 33% B, after which
the column was cleaned (0.6 min at 60% B and 2.1 min at 95% B) and
equilibrated (4.3 min at 3% B). Mass spectrometric detection was per-
formed using the following conditions: ESI positive, capillary voltage
3.5 kV, cone voltage 30 V, source oﬀset 50 V, source temperature
120 °C, cone gas (nitrogen) ﬂow 150 L/h, sheath (nanoﬂow) gas (ni-
trogen) ﬂow 0.2 bar, and collision gas (argon) ﬂow 0.15mL/min. MRM
transitions and settings for IGEPLVLK (selected for quantiﬁcation) and
VLSPQGGGPWDSVAR (selected for conﬁrmation) are presented in
Table S1 (Supplementary Information). The Ionkey/MS system was
operated under the Waters MassLynx software suite (version 4.1), and
the TargetLynx module of this package was used for data processing.
2.7. Method validation
The method was validated according to FDA and EMA guidelines,
and the following criteria were addressed: selectivity (e.g. spike re-
covery and ligand challenge tests), accuracy & precision, recovery,
calibration curve, and stability (e.g. 13 days benchtop, 10× freeze-
thaw, 4 months − 20 °C & − 80 °C storage, 28 days autosampler
(10 °C), and 443 days stock stability) [25,26]. For the recovery ex-
periment, 10 µL 50 ng/mL sRAGE was added to 240 µL serum (addition
of 2 ng/mL sRAGE;< 5% non-matrix solution in the ﬁnal sample) to
obtain the pre-IPE spiked samples, and 10 µL 10 ng/mL sRAGE was
added to IPE eluates (addition of 2 ng/mL) to obtain the post-IPE spiked
samples. The sRAGE dilutions for this experiment were prepared in
50mM ABC since adding Surrogate Matrix to the IPE eluates would
introduce excessive BSA to the samples thereby interfering with di-
gestion and LC-MS analysis. sRAGE in Surrogate Matrix was used for the
spike-recovery experiments, and the corresponding spiking procedure
was similar to that of the pre-IPE spiked samples of the recovery ex-
periment. Ligand challenge tests were performed by adding 200 ng of
fully-reduced HMGB1 (HMGBiotech, Milano, Italy; Cat. No. HM-116),
S100A12 (Novoprotein; Cat. No. C743), serum amyloid A1 (SAA1;
Novoprotein; Cat. No. C633), Nε-(carboxymethyl)lysine-modiﬁed bo-
vine serum albumin (CML-BSA; Academy Bio-Medical Co., Houston, TX,
U.S.A.; Cat. No. 30P-CML-BS102), or by adding 5% cigarette smoke
extract (the ﬁrst-hand smoke of two research cigarettes with ﬁlters cut
oﬀ (University of Kentucky, Lexington, KY, U.S.A.; Cat. No. 3R4F) was
pumped through 25mL of RMPI-1640 medium using a peristaltic pump
to obtain a 100% CSE solution) to the samples, or through addition of
5% A549 human alveolar epithelial cell lysate (10,000,000 cells/mL in
RMPI-1640 medium which were lysed by 30 s of sonication using a
probe sonicator followed by centrifugation for 5min at 1000× g to
pellet debris). For recovery and selectivity experiments, samples were
incubated for at least 30min following addition of sRAGE or the ligands
prior to initiating sRAGE immunocapture.
2.8. Method comparison
For method comparison, 40 serum samples were analyzed from a
cross-sectional study (NCT00807469) within the University Medical
Center Groningen (UMCG) [27]. For this study, ethical approval has
been granted by the UMCG's review board (METc 2008/136), and the
study adheres to the Declaration of Helsinki. Blood samples were col-
lected in plastic coagulation tubes (Becton Dickinson), which were in-
cubated for at least 30min at room temperature prior to centrifugation
at 1000× g and 4 °C for 10min. After collecting the serum fraction,
samples were aliquoted into 1.4mL polypropylene storage tubes
(Thermo Fisher, Cat. No. 3712), and stored at − 80 °C until further
analysis. In all 40 samples, sRAGE was quantiﬁed by LC-MS as well as
with the R&D Systems Human RAGE DuoSet (Cat. No. DY1145) and
Quantikine (Cat. No. DRG00) ELISA kits, both performed according to
manufacturer's instructions.
3. Results and discussion
3.1. Development of the simpliﬁed immunoprecipitation in 96-well ELISA
format (IPE) approach for sRAGE in serum
As serum sRAGE levels are reported to be in the low to sub ng/mL
range, enrichment of sRAGE prior to LC-MS analysis is required [16].
For this purpose, we adopted a strategy which builds upon the widely-
used microtiter plate-based format that forms the basis of most im-
munoassays. Our strategy furthermore represents a simpliﬁed version of
the previously described immunoprecipitation in 96-well ELISA format
(IPE) [11] for which we particularly aimed to circumvent the need to
use Protein (A/)G coated plates (comparable with previously published
approaches [9,10]) as non-occupied Protein (A/)G residues may favor
non-speciﬁc binding and thus may lead to increased background signals
[28]. Accordingly, the resulting approach initially follows the typical
steps of an ELISA, but instead of adding a secondary antibody for signal
ampliﬁcation and detection, enriched proteins are eluted from the
capturing antibody. Proteins can subsequently be studied in their intact
form by mass spectrometry and Western Blot analysis, or can be di-
gested with a protease (e.g. trypsin) and analyzed by LC-MS, which was
the selected strategy for our sRAGE assay. Optimization of the amount
of antibody per sample (see Fig. S1) revealed that less than 0.5 µg of
antibody was needed to detect sRAGE at clinically relevant levels with
sensitivity down to 0.1 ng/mL (see Fig. 1). The required amount of
antibody obviously depends greatly on the dissociation constant (Kd)
and quality of an antibody [28], yet 0.25–0.5 µg of antibody per sample
corresponds well with the amounts that are generally used for im-
munoassays and is furthermore eight to twenty times lower than the
amounts that were previously used in IPE protocols [11].
3.2. Selection of internal standard and calibration matrix
Stable-isotope-labeled (SIL) versions of authentic analytes are the
internal standards of choice to enable adequate correction for varia-
bility arising from sample preparation or LC-MS, particularly when an
immunopuriﬁcation step is included for analyte enrichment [29,30].
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Unfortunately, such standards are often not available (in suﬃcient
quality) for intact proteins, as is the case for sRAGE. Consequently, SIL
versions of selected proteotypic peptides were employed as internal
standards which were added to the samples after the IPE procedure. To
check whether this strategy introduces a bias, recovery of sRAGE during
IPE was evaluated during method validation revealing a consistently
high and precise recovery of sRAGE using the IPE protocol (see the
Assay characteristics section below).
For selection of proteotypic peptides, Skyline software (version
3.5.0.9319; UniProtKB reference proteome: ‘UP000005640 canonical
+ isoforms’) and the online MRM Peptide Picking Tool (version 1.0;
UniProtKB entry: ‘Q15109’) were employed [31,32]. Trypsin was se-
lected as protease, and peptides were evaluated on the basis of their
uniqueness, presence in the mature protein, presence in relevant iso-
forms (e.g. esRAGE), peptide length, absence of post translational
modiﬁcation (PTM) sites (e.g. N-linked glycosylation), and location
close to or, preferably, within the N-terminal domain of sRAGE which is
most relevant for ligand binding [14,24]. In addition, genetic variation
was considered by consulting the ExAC Browser (version 0.3; Ensembl
gene: ‘ENSG00000204305′) and peptides encompassing highly pre-
valent SNP-sites (e.g. rs2070600 SNP leading to the Gly82Ser sub-
stitution) were excluded [33]. Upon in silico evaluation of proteotypic
peptides as well as empirical assessment of their ESI-ionization prop-
erties, the following two peptides were selected for further method
development: r. IGEPLVLK.c (30–37) and k. VLSPQGGGPWDSVAR.v
(63–77). Since the IGEPLVLK peptide performed best in terms of ac-
curacy and precision during method validation, this peptide was se-
lected for sRAGE quantiﬁcation (quantiﬁer peptide), whereas the
VLSPQGGGPWDSVAR peptide was used to conﬁrm the presence of
sRAGE (qualiﬁer peptide).
With respect to selection of the calibration matrix, employing an
authentic matrix for preparation of the calibration samples would be
preferable, yet an analyte-free, authentic matrix could not be obtained
[29]. Accordingly, several surrogate matrices were evaluated including
complex matrices (e.g. fetal calf serum) as well as a simple, artiﬁcial
matrix consisting of 1% BSA in PBS. The recovery of spiked (re-
combinant human) sRAGE from these matrices was comparable to that
of spiked sRAGE from human serum (see Fig. S2). Therefore, 1% BSA in
PBS was selected as surrogate matrix and its suitability was demon-
strated during method validation (see the Assay characteristics section
below).
3.3. Assay characteristics
A concise summary of the validation results is presented in Table 1
while a full overview is given in Tables S2 to S19 (Supplementary
Information). Accurate quantiﬁcation of sRAGE was demonstrated for a
1/x weighted linear calibration model using 8 non-zero standards be-
tween 0.1 ng/mL (LLOQ: CV & bias± 10%) and 10 ng/mL (see Tables
S2 and S3). Evaluation of accuracy and precision revealed comparable
biases and CVs for all three QC-levels (approximately± 5% and 10%,
respectively) suggesting that methodological variation due to the IPE
procedure (for which an internal standard to compensate for metho-
dological variability is absent) is constant for low, midrange, and high
sRAGE levels and within the approved limits for regulated bioanalysis
(see Tables S4 to S6). The extent of the IPE recovery was consistently
high ranging from 81% to 84% and precise (CVs of 6–7%) regardless of
whether the average of duplicate measurements or individual replicates
were considered (see Table S16). Accordingly, these data justify
quantifying sRAGE by single measurements which entails that LC-MS
analysis of samples from one 96-well microtiter plate (i.e. 81 clinical
samples, 9 calibrants, and 6 QC-samples) can be performed within two
days.
Sample stability was assessed under conditions going beyond what
is relevant for typical clinical assays after 13 days of storage on the
benchtop (room temperature), 4 months of storage in the freezer
(− 20 °C and − 80 °C), and upon 10 freeze-thaw cycles (See Tables S9
to S14). These stability assessments indicated that sRAGE is a rather
stable biomarker with respect to IPE enrichment and the proteotypic
peptide that is used for sRAGE quantiﬁcation by LC-MS.
Selectivity of the sRAGE method was studied by spike-recovery and
ligand challenge testing. Spike-recovery experiments were carried out
using six diﬀerent sources of serum which were processed in duplicate.
The observed biases were within± 15% when either the average
sRAGE level of both replicates or the levels of the individual replicates
were assessed. With respect to these data, it should be noted that one of
the samples (subject ♂3, see Table S17) contributed mostly to the
observed (negative) bias. The reason for this diﬀerence is currently
unclear. Even though the overall bias is within acceptable limits, this
observation indicates that employing a whole-protein SIL internal
standard should be considered as relevant future enhancement for our
assay. Moreover, spike-recovery assessment was extended to a hemo-
lytic and a lipemic sample which yielded biases within± 15% as well
(see Table S18). For evaluation of potential interfering ligands, we se-
lected high mobility group box 1 protein (HMGB1) which is the most
studied and characterized RAGE ligand [21,34], S100 calcium-binding
protein A12 (S100A12) and serum amyloid A1 (SAA1) as examples of
damage-associated molecular pattern (DAMP) proteins known to bind
RAGE [35,36], and Nε-(carboxymethyl)lysine-modiﬁed bovine serum
albumin (CML-BSA) was included as a surrogate for advanced glycation
end-product-modiﬁed proteins [17]. All ligands were added at 4 µg/mL
(> 10,000-times molar excess). Furthermore, we aimed to mimic po-
tential interferences arising from cigarette smoking by challenging
samples with cigarette smoke extract (CSE) in view of future studies on
COPD patients. Since many RAGE ligands are DAMPs which are re-
leased upon cigarette smoke-induced cell death, we also studied po-
tential interferences by challenging samples with lysed human alveolar
epithelial A549 cells [37,38]. Ultimately, none of the tested ligands
aﬀected the measured sRAGE levels (see Table S19), as reported pre-
viously for the Quantikine sRAGE ELISA as well [39].
3.4. Method comparison
Agreement between the LC-MS sRAGE assay and two widely-used
sRAGE immunoassays (i.e. R&D Systems DuoSet and Quantikine ELISAs
for RAGE) was assessed on the basis of 40 clinical samples using linear
regression and Bland-Altman plots (see Fig. 2). These comparisons re-
vealed substantial correlations between the LC-MS assay and the
DuoSet and Quantikine ELISAs with coeﬃcients of determination of
0.72 and 0.79, respectively, as well as substantial correlation between
the immunoassays (R2 = 0.80). However, sRAGE levels obtained with
the ELISAs were considerably lower than those obtained by the LC-MS
assay with average relative diﬀerences of− 84% and− 131% (2.0 and
3.9 times lower sRAGE levels) for the Quantikine and DuoSet ELISAs,
respectively.
Possible explanations for the observed diﬀerences in sRAGE levels
Fig. 1. Selected Ion Chromatograms of the sRAGE-derived proteotypic peptides (A)
IGEPLVLK and (B) VLSPQGGGPWDSVAR at 0.1 ng/mL in Surrogate Matrix (1% BSA in
1×PBS, pH 7.4).
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Table 1
Summary of validation data a.
QC-low QC-medium QC-high
CV Biasb CV Biasb CV Biasb
Accuracy & precision (3 runs, in 6-fold) Run 1 12% −5% 11% 1% 4% 1%
Run 2 10% 1% 5% 7% 6% 4%
Run 3 8% 4% 14% −8% 11% −5%
Autosampler stability 10 °C (28 days, in 3-fold) 1% 2% 1% −4%
Bench-top stability room temperature (13 days, in 3-fold) 6% 2% 1% 5%
Freeze-thaw stability −20 °C (10 cycles, in 3-fold) 7% 0% 12% −8%
Storage stability −20 °C (4 months, in 3-fold) 11% −7% 2% −2%
Storage stability −80 °C (4 months, in 3-fold) 7% −3% 6% 3%
10 ng/mL calibrant
CV Bias
stock stability −20 °C (443 days, in 5-fold) 3% 1%
Replicate 1 Replicate 2 Average of replicates
Recovery CV Recovery CV Recovery CV
recovery (6 diﬀerent plasma samples, 1 or 2 technical replicates) 81% 6% 84% 7% 83% 6%
Replicate 1 Replicate 2 Average of replicates
Bias Bias Bias
spike recovery (6 diﬀerent plasma samples, 1 or 2 technical replicates) −10% −13% −12%
Bias
lipemic sample spike recovery (in 2-fold) −13%
hemolytic sample spike recovery (in 2-fold) −8%
0.2 ng/mL calibrant 0.2 ng/mL calibrant
CV Bias CV Bias
HMGB1 challenge test (4 µg/mL, in 5-fold) 6% 10% CML-BSA challenge test (4 µg/mL, in 5-fold) 12% 4%
S100A12 challenge test (4 µg/mL, in 5-fold) 4% 12% CSE challenge test (5%, in 5-fold) 6% −8%
SAA1 challenge test (4 µg/mL, in 5-fold) 9% 7% Cell lysate challenge test (5%, in 5-fold) 6% −1%
a An extensive summary of the validation results is presented in Tables S2 to S19 (Supplementary Information).
b The average value of measured concentrations during the precision and accuracy experiments was used as nominal concentration.
Fig. 2. Comparisons between the quantitative IPE LC-MS sRAGE method (average levels), the R&D Systems Human RAGE DuoSet ELISA, and the R&D Systems Human RAGE Quantikine
ELISA using (A) linear regression and (B) Bland-Altman plots. Comparisons between the results of the individual IPE replicates and data from both ELISAs are shown in Fig. S3
(Supplementary Information).
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obtained by the assays include diﬀerent speciﬁcities for the antibodies
used in the assays (information on the epitopes is not available), in-
complete capture of sRAGE from serum due to an insuﬃcient amount of
primary antibody in the immunoassays as well as diﬀerences between
the declared and the actual protein quantities of the sRAGE stocks used
for preparation of the calibration curves. The latter two explanations
were investigated by increasing the amount of antibody for the DuoSet
ELISA whose design is rather ﬂexible thereby allowing to deviate from
recommended protocol, from 0.1 µg (manufacturer's recommendation;
this amount was actually insuﬃcient for the IPE method, see Figure S1)
to 0.5 µg per sample (i.e. the amount used for IPE). Furthermore, the
DuoSet sRAGE standard was quantiﬁed using the LC-MS assay, and
ELISA data were corrected for the observed diﬀerence between the
expected and the actual sRAGE concentrations (4.0 and 2.9 ng/mL,
respectively) as measured by LC-MS. Upon increasing the amount of
antibody, signals for the ELISA increased signiﬁcantly (see ‘0.1 µg’ and
‘0.5 µg’ in Fig. 3) yielding sRAGE levels comparable with those obtained
by the LC-MS assay for the QC-low sample, albeit to a lesser extent for
the QC-medium and QC-high samples. Referencing the ELISA protein
stock against that of the LC-MS assay, however, led to a downward
adjustment of the sRAGE levels determined by ELISA (see ‘0.1 µg corr.’
and ‘0.5 µg corr.’ in Fig. 3). Increasing the amount of capturing anti-
body in the ELISA was thus the most important factor to bring the re-
sults more in line with the IPE assay. However, it is conceivable that
optimizing the calibration strategy of the ELISA, for example by em-
ploying a surrogate matrix which better resembles the complexity and
composition of serum than the surrogate matrix used for the ELISA (i.e.
1% BSA in PBS), furthermore represents a strategy to improve the ac-
curacy of this particular assay.
The remaining bias may be the result of the diﬀerent detection
principles of both assay platforms. Whereas readouts of an ELISA are
indirect and rely on the ability of a detection antibody to bind the target
molecule in order to generate a signal, LC-MS-based approaches analyze
the target molecule based on protein-speciﬁc peptides. This readout is
thus based on conﬁned chemical information which in case of our
method relates to whether a circulating RAGE molecule (enriched by
IPE) contains the IGEPLVLK sequence. Considering this principle, a
form of RAGE lacking the N-terminal domain which is essential for
binding of RAGE to most of its ligands, will not be picked up by the MS-
based assay, as both the quantiﬁer and qualiﬁer peptides are located in
the N-terminal domain [14,24]. Furthermore, the MS-based method
does not discriminate between circulating RAGE formed upon shedding
of membrane-bound RAGE by metalloproteases and esRAGE which is
produced by alternative splicing of the AGER gene, since the N-terminal
domain is preserved in both proteoforms [15]. Thus, results obtained
with the diﬀerent assay platforms are prone to be diﬀerent due to the
distinct detection principles of both platforms and the expected het-
erogeneity of circulating RAGE molecules.
3.5. Perspectives for the IPE assay
The IPE approach is easy to set up and use, antibody eﬃcient, and a
robust strategy for enriching low-abundant proteins like sRAGE from
highly complex biological samples such as serum. It is conceivable that
this assay format can be applied to other low-abundant proteins in
other biological matrices and possibly also for studying protein-protein
interactions or with the purpose of ﬁnding missing proteins (of low
abundance) [40,41]. In fact, the IPE principle is currently being in-
vestigated for pull-down assays of low-abundant, intracellular proteins
with encouraging results (data not shown). With respect to future ap-
plications, it should however be noted that the IPE Wash Buﬀer con-
tains Tween-20 which proved to be necessary for recovery of sRAGE,
but which may interfere with LC-MS analyses. In our case, Tween-20
did not present diﬃculties, and remaining detergent in the LC system
was removed by regularly ﬂushing the LC ﬂow paths with high per-
centages of eluent B. This may not be possible for some other appli-
cations, and washing conditions may need to be optimized accordingly.
Moreover, the use of surfactants that can be removed more easily or
that are more compatible with ESI-MS comprises another area that
needs to be investigated.
4. Conclusions
The simpliﬁed immunoprecipitation in 96-well ELISA format (IPE)
methodology is an easy and eﬃcient platform for immunoaﬃnity en-
richment. Its potential for enriching proteins from complex matrices
was demonstrated in a mass spectrometry-based workﬂow to quantify
the low-abundant biomarker sRAGE in human serum. The method was
validated according to U.S. Food and Drug Administration and
European Medicines Agency guidelines and enabled quantiﬁcation of
sRAGE in human serum at clinically relevant levels (between 0.1 and
10 ng/mL). Comparison of this assay with the two most widely-used
sRAGE ELISAs revealed substantial correlation between all three assays;
however, IPE LC-MS reported 2–4 times higher sRAGE levels compared
to the ELISAs. This discrepancy can largely be explained by an in-
suﬃcient amount of capturing antibody per well used by the ELISAs to
capture all sRAGE in serum samples, though an improper calibration
strategy of the ELISA and the diﬀerent detection principles of both
assay platforms may provide partial explanations as well. In conclusion,
the IPE format allows to eﬃciently establish immunoaﬃnity enrich-
ment strategies which may simplify and foster the study of proteins in
complex matrices.
Fig. 3. sRAGE levels for the (A) QC-low, (B) QC-medium, and (C) QC-high samples as measured by the DuoSet ELISA using 0.1 µg (manufacturer's recommendation; N =2) and 0.5 µg of
capturing antibody per well (N= 2), and also as measured by IPE LC-MS (nominal sRAGE levels as determined during validation). ELISA calibration was performed with the supplied
sRAGE protein standard either using the protein quantity as declared by the manufacturer (‘0.1 µg’ and ‘0.5 µg’) or by using the corrected protein quantity upon referencing the ELISA
protein standard against the protein standard of the LC-MS method (‘0.1 µg corr.’ and ‘0.5 µg corr.’).
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